COLL · Collegium Pharmaceutical, Inc · Executive Compensation
$23.59
+0.67 (+2.92%)
At close · Oct 22
Return incl. dividend (before tax)
Market Cap
$746.01M
Shares
32.56M
Volume · Oct 22
203.15K
Avg daily vol (3M)
781.51K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| David Dieter | Executive Vice President and General Counsel | $3,870,092 |
| Colleen Tupper | Executive Vice President and Chief Financial Officer | $3,515,055 |
| Scott Dreyer | Executive Vice President and Chief Commercial Officer | $3,041,212 |
| Thomas Smith | Executive Vice President and Chief Medical Officer | $2,446,008 |
| Vikram Karnani | President and Chief Executive Officer | $1,715,846 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Vikram Karnani | President and Chief Executive Officer | $10,780,125 |
| Joseph Ciaffoni | Former President and Chief Executive Officer | $10,689,852 |
| Shirley Kuhlmann | Former Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | $3,301,296 |
| Colleen Tupper | Executive Vice President and Chief Financial Officer | $3,189,972 |
| Scott Dreyer | Executive Vice President and Chief Commercial Officer | $2,791,375 |
| Thomas Smith | Executive Vice President and Chief Medical Officer | $2,500,083 |
| Michael Heffernan | R.Ph. Former Interim President and Chief Executive Officer | $466,455 |
| David Dieter | Executive Vice President and General Counsel | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Joseph Ciaffoni | Former President and Chief Executive Officer | $9,142,924 |
| Shirley Kuhlmann | Former Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | $2,874,147 |
| Colleen Tupper | Executive Vice President and Chief Financial Officer | $2,734,857 |
| Scott Dreyer | Executive Vice President and Chief Commercial Officer | $2,612,380 |
| Thomas Smith | Executive Vice President and Chief Medical Officer | $2,044,802 |
| Michael Heffernan | R.Ph. Former Interim President and Chief Executive Officer | — |
| Vikram Karnani | President and Chief Executive Officer | — |
| David Dieter | Executive Vice President and General Counsel | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Joseph Ciaffoni | Former President and Chief Executive Officer | $6,917,530 |
| Shirley Kuhlmann | Former Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | $2,431,162 |
| Colleen Tupper | Executive Vice President and Chief Financial Officer | $2,318,904 |
| Scott Dreyer | Executive Vice President and Chief Commercial Officer | $2,217,192 |
| Richard Malamut | Former Executive Vice President and Chief Medical Officer | $1,664,235 |
| Thomas Smith | Executive Vice President and Chief Medical Officer | $600,517 |
| Michael Heffernan | R.Ph. Former Interim President and Chief Executive Officer | — |
| Vikram Karnani | President and Chief Executive Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Joseph Ciaffoni | President and Chief Executive Officer | $7,314,335 |
| Shirley Kuhlmann | Executive Vice President, Chief Administrative Officer, General Counsel & Secretary | $2,394,276 |
| Scott Dreyer | Executive Vice President and Chief Commercial Officer | $2,381,596 |
| Colleen Tupper | Executive Vice President and Chief Financial Officer | $2,299,575 |
| Richard Malamut | Former Executive Vice President and Chief Medical Officer | $2,057,818 |
| Thomas Smith | Executive Vice President and Chief Medical Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Joseph Ciaffoni | President and Chief Executive Officer | $6,042,639 |
| Shirley Kuhlmann | Executive Vice President, Chief Administrative Officer, General Counsel & Secretary | $2,096,181 |
| Richard Malamut | Former Executive Vice President and Chief Medical Officer | $1,761,807 |
| Scott Dreyer | Executive Vice President and Chief Commercial Officer | $1,716,467 |
| Colleen Tupper | Executive Vice President and Chief Financial Officer | — |
| Thomas Smith | Executive Vice President and Chief Medical Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Thomas Smith, M.D. | Executive Vice President and Chief Medical Officer | Terminated | 2026-05-12 |
| Scott Dreyer | Executive Vice President and Chief Commercial Officer | Terminated | 2026-05-12 |
| Gino Santini | Director | Appointed | 2025-05-19 |
| Carlos Paya | Director | Appointed | 2025-05-19 |
| Vikram Karnani | Director | Appointed | 2025-05-19 |
| John Freund | Director | Appointed | 2025-05-19 |
| Nancy Lurker | Director | Appointed | 2025-05-19 |
| John Fallon | Director | Appointed | 2025-05-19 |
| Garen Bohlin | Director | Appointed | 2025-05-19 |
| Rita Balice-Gordon | Director | Appointed | 2025-05-19 |
| David Dieter | Executive Vice President and General Counsel | Appointed | 2025-03-17 |
| Nancy S. Lurker | Collegium's Board of Directors | Appointed | 2025-02-27 |
| Nancy Lurker | director | Appointed | 2025-02-05 |
| Vikram Karnani | member of the Board | Appointed | 2024-11-07 |
| Vikram Karnani | President and Chief Executive Officer | Appointed | 2024-11-07 |
| Neil McFarlane | Board | Resigned | 2024-07-29 |
| Michael Heffernan | Interim President and Chief Executive Officer | Appointed | 2024-05-24 |
| Michael Heffernan | Interim President and Chief Executive Officer | Appointed | 2024-05-10 |
Leadership
- Gino Santini Chairman, Board Member
- David Dieter General Counsel
- Shirley Kuhlmann General Counsel
- Carlos Paya Board Member
- Dr. Rita Balice-Gordon, Ph.D. Board Member
- Garen Bohlin Board Member
- John Fallon Board Member
- John Freund Board Member
- Joseph Ciaffoni Board Member
- Nancy Lurker Board Member
- Nancy S. Lurker Board Member
- Neil F. McFarlane Board Member
- Rita Balice-Gordon Board Member
- Vikram Karnani Board Member
Key facts
CIK
1267565
CUSIP
19459J104
13F (30d)
22 filings
22 filers
Visit website
Investor relations